Although sestrin mutations are rare (≤0.8%), SESN1 deep deletion is a frequent event in prostate cancer occurring in 4.7–13.4% of cases (Tables S1–S3), potentially leading to increased mTORC1 signaling through alleviation of SESN1-mediated negative regulation of mTORC1. This evidence concerns the gene SESN1 and prostate cancer.